Lead asset VK2735: dual GLP-1/GIP in oral and injectable formulations. VENTURE-Oral Phase 2 hit 10.9% placebo-adjusted weight loss at 13 weeks. Most-discussed mid-cap obesity pure-play; repeated M&A speculation.
Lead asset VK2735: dual GLP-1/GIP in oral and injectable formulations. VENTURE-Oral Phase 2 hit 10.9% placebo-adjusted weight loss at 13 weeks. Most-discussed mid-cap obesity pure-play; repeated M&A speculation.
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling: